{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:23:32Z","timestamp":1790695412855,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006304","name":"Aalborg University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hypothalamic obesity is a severe complication of craniopharyngioma, marked by hyperphagia and rapid weight gain. Glucagon-like peptide-1 receptor agonists such as semaglutide have shown promising effects on weight reduction, but long-term data on weight outcomes, metabolic parameters and quality-of-life remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four female patients with hypothalamic obesity following craniopharyngioma treatment received semaglutide for 24 months. Assessments included DXA scans, metabolic biomarkers, and The Three-Factor Eating Questionnaire at baseline, 6, 12, and 24 months. Interviews at 24 months explored hunger, side effects and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 24 months, median weight loss was 16% (95% CI: 8 to 34%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), with maximal loss of 17% at 6 months. Emotional and uncontrolled eating scores (range: 0\u2013100) decreased by 44 (95% CI: \u2212\u200969 to \u2212\u200919,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) and 27 units (95% CI: \u2212\u200963 to 9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.097), respectively. Interviews revealed reduced hunger, improved self-confidence, less isolation, and higher productivity. Treatment was well tolerated; side effects were mainly mild GI symptoms. Fat and lean mass decreased by 10% (95% CI: 2 to 44%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016) and 19% (95% CI: 14 to 26%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), respectively, with stable bone mineral content. Hemoglobin A1c and LDL cholesterol declined by 6.4 mmol\/mol (95% CI: 2.3 to 9.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016) and 0.5 mmol\/L (95% CI: 0.3 to 0.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide is a safe treatment that led to long-term sustained improvements in eating behavior, weight control, and improved metabolic health. Patients reported an improved quality of life, which persisted after body weight stabilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01564-7","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T18:50:12Z","timestamp":1755629412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life"],"prefix":"10.1007","volume":"28","author":[{"given":"Erlend","family":"Gjersdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik \u00d8stergaard","family":"Klit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re","family":"Schmidt Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9046-2967","authenticated-orcid":false,"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-3557","authenticated-orcid":false,"given":"Eigil Husted","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Nilsson","family":"Vistisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4929-9966","authenticated-orcid":false,"given":"Hermann L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Melgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0610-7867","authenticated-orcid":false,"given":"Jakob","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12527","volume":"14","author":"AM Daubenb\u00fcchel","year":"2019","unstructured":"Daubenb\u00fcchel AM, \u00d6zyurt J, Boekhoff S et al (2019) Eating behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of hypothalamic involvement. Pediatr Obes 14:e12527. https:\/\/doi.org\/10.1111\/ijpo.12527","journal-title":"Pediatr Obes"},{"key":"1564_CR2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1547660","author":"A Hoffmann","year":"2015","unstructured":"Hoffmann A, Postma FP, Gebhardt U, M\u00fcller H (2015) Eating behaviour and weight problems in long-term survivors of childhood craniopharyngioma\u2013 Results of the hit Endo trial. Exp Clin Endocrinol Diabetes 122. https:\/\/doi.org\/10.1055\/s-0035-1547660","journal-title":"Exp Clin Endocrinol Diabetes 122"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cen.12523","volume":"82","author":"J Roemmler-Zehrer","year":"2015","unstructured":"Roemmler-Zehrer J, Geigenberger V, St\u00f6rmann S et al (2015) Specific behaviour, mood and personality traits may contribute to obesity in patients with craniopharyngioma. Clin Endocrinol (Oxf) 82:106\u2013114. https:\/\/doi.org\/10.1111\/cen.12523","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12160-010-9192-6","volume":"39","author":"MR Stolley","year":"2010","unstructured":"Stolley MR, Restrepo J, Sharp LK (2010) Diet and physical activity in childhood cancer survivors: a review of the literature. Ann Behav Med 39:232\u2013249. https:\/\/doi.org\/10.1007\/s12160-010-9192-6","journal-title":"Ann Behav Med"},{"key":"1564_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jada.2011.09.004","volume":"111","author":"H Badr","year":"2011","unstructured":"Badr H, Paxton RJ, Ater JL et al (2011) Health behaviors and weight status of childhood cancer survivors and their parents: similarities and opportunities for joint interventions. J Am Diet Assoc 111:1917\u20131923. https:\/\/doi.org\/10.1016\/j.jada.2011.09.004","journal-title":"J Am Diet Assoc"},{"key":"1564_CR6","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1210\/jc.2010-0993","volume":"95","author":"H Holmer","year":"2010","unstructured":"Holmer H, Pozarek G, Wirf\u00e4lt E et al (2010) Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab 95:5395\u20135402. https:\/\/doi.org\/10.1210\/jc.2010-0993","journal-title":"J Clin Endocrinol Metab"},{"key":"1564_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-04987-1","author":"HL M\u00fcller","year":"2025","unstructured":"M\u00fcller HL (2025) Long-term quality of life and hypothalamic dysfunction after craniopharyngioma. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-025-04987-1","journal-title":"J Neurooncol"},{"key":"1564_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","volume":"8","author":"HL M\u00fcller","year":"2022","unstructured":"M\u00fcller HL, Tauber M, Lawson EA et al (2022) Hypothalamic syndrome. Nat Rev Dis Primers 8:24. https:\/\/doi.org\/10.1038\/s41572-022-00351-z","journal-title":"Nat Rev Dis Primers"},{"key":"1564_CR9","doi-asserted-by":"publisher","unstructured":"Erfurth EM, M\u00fcller HL (2025) Metabolic complications and their mechanisms in patients with craniopharyngioma. Best Pract Res Clin Endocrinol Metab 101999. https:\/\/doi.org\/10.1016\/j.beem.2025.101999","DOI":"10.1016\/j.beem.2025.101999"},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s11102-024-01443-7","volume":"27","author":"F Prodam","year":"2024","unstructured":"Prodam F (2024) Is semaglutide a target therapy for acquired hypothalamic obesity? Pituitary 27:444\u2013448. https:\/\/doi.org\/10.1007\/s11102-024-01443-7","journal-title":"Pituitary"},{"key":"1564_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ecl.2020.05.009","volume":"49","author":"HL M\u00fcller","year":"2020","unstructured":"M\u00fcller HL (2020) Management of hypothalamic obesity. Endocrinol Metab Clin North Am 49:533\u2013552. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","volume":"25","author":"NC Bergmann","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK (2023) Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab 25:18\u201335. https:\/\/doi.org\/10.1111\/dom.14863","journal-title":"Diabetes Obes Metab"},{"key":"1564_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae024","author":"B Gatta-Cherifi","year":"2024","unstructured":"Gatta-Cherifi B, Mohammedi K, Cariou T et al (2024) Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol. https:\/\/doi.org\/10.1093\/ejendo\/lvae024","journal-title":"Eur J Endocrinol"},{"key":"1564_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000509302","volume":"13","author":"J van Schaik","year":"2020","unstructured":"van Schaik J, Begijn DGA, van Iersel L et al (2020) Experiences with glucagon-like peptide-1 receptor agonist in children with acquired hypothalamic obesity. Obes Facts 13:361\u2013370. https:\/\/doi.org\/10.1159\/000509302","journal-title":"Obes Facts"},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/oby.21493","volume":"24","author":"JP Lomenick","year":"2016","unstructured":"Lomenick JP, Buchowski MS, Shoemaker AH (2016) A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity 24:1222\u20131225. https:\/\/doi.org\/10.1002\/oby.21493","journal-title":"Obesity"},{"issue":"2","key":"1564_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","volume":"23","author":"CL Roth","year":"2021","unstructured":"Roth CL, Perez FA, Whitlock KB et al (2021) A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab 23(2):363\u2013373. https:\/\/doi.org\/10.1111\/dom.14224","journal-title":"Diabetes Obes Metab"},{"key":"1564_CR17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2169\/internalmedicine.53.1646","volume":"53","author":"T Ando","year":"2014","unstructured":"Ando T, Haraguchi A, Matsunaga T et al (2014) Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity. Intern Med 53:1791\u20131795. https:\/\/doi.org\/10.2169\/internalmedicine.53.1646","journal-title":"Intern Med"},{"key":"1564_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/EJE-12-0997","volume":"168","author":"F Zoicas","year":"2013","unstructured":"Zoicas F, Droste M, Mayr B et al (2013) GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol 168:699\u2013706. https:\/\/doi.org\/10.1530\/EJE-12-0997","journal-title":"Eur J Endocrinol"},{"key":"1564_CR19","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0493","author":"M He","year":"2024","unstructured":"He M, Xu H, Ying Z et al (2024) Effectiveness of bariatric surgery on acquired hypothalamic obesity: a systematic review and meta-analysis. Endocr Connect 13. https:\/\/doi.org\/10.1530\/EC-24-0493","journal-title":"Endocr Connect 13"},{"key":"1564_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21:201\u2013223. https:\/\/doi.org\/10.1038\/s41573-021-00337-8","journal-title":"Nat Rev Drug Discov"},{"key":"1564_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ et al (2020) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.133429","journal-title":"JCI Insight"},{"key":"1564_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02392-0","author":"ACS Pierret","year":"2024","unstructured":"Pierret ACS, Benton M, Sen Gupta P, Ismail K (2024) A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-024-02392-0","journal-title":"Acta Diabetol"},{"key":"1564_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad074","volume":"1","author":"C Sciacovelli","year":"2023","unstructured":"Sciacovelli C, Moschione G, Garelli S, Pagotto U (2023) Semaglutide for treating obesity induced by craniopharyngioma resection: a successful case study. JCEM Case Reports 1:luad074. https:\/\/doi.org\/10.1210\/jcemcr\/luad074","journal-title":"JCEM Case Reports"},{"key":"1564_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11102-024-01426-8","volume":"27","author":"E Gjersdal","year":"2024","unstructured":"Gjersdal E, Larsen LB, Ettrup KS et al (2024) Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma. Pituitary 27:723\u2013730. https:\/\/doi.org\/10.1007\/s11102-024-01426-8","journal-title":"Pituitary"},{"key":"1564_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11102-024-01429-5","volume":"27","author":"M Svendstrup","year":"2024","unstructured":"Svendstrup M, Rasmussen AK, Kistorp C et al (2024) Semaglutide treatment of hypothalamic obesity - a real-life data study. Pituitary 27:685\u2013692. https:\/\/doi.org\/10.1007\/s11102-024-01429-5","journal-title":"Pituitary"},{"key":"1564_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/cen.15262","author":"X Wang","year":"2025","unstructured":"Wang X, Ma H, Wang F et al (2025) The efficacy of semaglutide on hypothalamic obesity caused by craniopharyngioma surgery. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.15262","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1564_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.aed.2025.03.004","author":"S Brijmohan","year":"2025","unstructured":"Brijmohan S, Mullally JA (2025) Successful treatment of hypothalamic obesity with tirzepatide. AACE Endocrinol Diabetes. https:\/\/doi.org\/10.1016\/j.aed.2025.03.004","journal-title":"AACE Endocrinol Diabetes"},{"key":"1564_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1089\/jayao.2015.0058","volume":"5","author":"MC Swartz","year":"2016","unstructured":"Swartz MC, Basen-Engquist KM, Markham C et al (2016) Psychometric analysis of the Three-Factor eating Questionnaire-R18V2 in adolescent and young Adult-Aged central nervous system tumor survivors. J Adolesc Young Adult Oncol 5:278\u2013285. https:\/\/doi.org\/10.1089\/jayao.2015.0058","journal-title":"J Adolesc Young Adult Oncol"},{"key":"1564_CR29","volume-title":"InterViews","author":"S Brinkmann","year":"2014","unstructured":"Brinkmann S, Kvale S (2014) InterViews, 3rd edn. SAGE, Thousand Oaks, CA","edition":"3"},{"key":"1564_CR30","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V (2012) Thematic analysis. APA handbook of research methods in psychology, vol 2: research designs: quantitative, qualitative, neuropsychological, and biological. American Psychological Association, Washington, pp 57\u201371","DOI":"10.1037\/13620-004"},{"issue":"3","key":"1564_CR31","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S et al (2021) The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 23(3):754\u2013762. https:\/\/doi.org\/10.1111\/dom.14280","journal-title":"Diabetes Obes Metab"},{"key":"1564_CR32","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M et al (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19:1242\u20131251. https:\/\/doi.org\/10.1111\/dom.12932","journal-title":"Diabetes Obes Metab"},{"key":"1564_CR33","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1111\/dom.15823","volume":"26","author":"Y Baba","year":"2024","unstructured":"Baba Y, Watanabe S, Hayashi S et al (2024) Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 26:4787\u20134790. https:\/\/doi.org\/10.1111\/dom.15823","journal-title":"Diabetes Obes Metab"},{"key":"1564_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2343092","author":"A Bikou","year":"2024","unstructured":"Bikou A, Dermiki-Gkana F, Penteris M et al (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. https:\/\/doi.org\/10.1080\/14656566.2024.2343092","journal-title":"Expert Opin Pharmacother"},{"key":"1564_CR35","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"Hansen MS, W\u00f6lfel EM, Jeromdesella S et al (2024) Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine 72:102624. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102624","journal-title":"EClinicalMedicine"},{"key":"1564_CR36","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren JR, Hartmann B et al (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 100:2909\u20132917. https:\/\/doi.org\/10.1210\/jc.2015-1176","journal-title":"J Clin Endocrinol Metab"},{"key":"1564_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"Hygum K, Harsl\u00f8f T, J\u00f8rgensen NR et al (2020) Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone 132:115197. https:\/\/doi.org\/10.1016\/j.bone.2019.115197","journal-title":"Bone"},{"key":"1564_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4158\/EP15758.OR","volume":"22","author":"MP Gilbert","year":"2016","unstructured":"Gilbert MP, Marre M, Holst JJ et al (2016) Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr Pract 22:406\u2013411. https:\/\/doi.org\/10.4158\/EP15758.OR","journal-title":"Endocr Pract"},{"key":"1564_CR39","doi-asserted-by":"publisher","first-page":"3361309","DOI":"10.1155\/2021\/3361309","volume":"2021","author":"T-T Cai","year":"2021","unstructured":"Cai T-T, Li H-Q, Jiang L-L et al (2021) Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: A 52-week clinical study. Biomed Res Int 2021:3361309. https:\/\/doi.org\/10.1155\/2021\/3361309","journal-title":"Biomed Res Int"},{"key":"1564_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035394","volume":"102","author":"OZ Akyay","year":"2023","unstructured":"Akyay OZ, Canturk Z, Selek A et al (2023) The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine 102:e35394. https:\/\/doi.org\/10.1097\/MD.0000000000035394","journal-title":"Medicine"},{"key":"1564_CR41","doi-asserted-by":"publisher","first-page":"e59558","DOI":"10.7759\/cureus.59558","volume":"16","author":"P Tzoulis","year":"2024","unstructured":"Tzoulis P, Batavanis M, Baldeweg S (2024) A real-world study of the effectiveness and safety of semaglutide for weight loss. Cureus 16:e59558. https:\/\/doi.org\/10.7759\/cureus.59558","journal-title":"Cureus"},{"key":"1564_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima S-I, Tsoukas GM et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5:251\u2013260. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1564_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397:971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"1564_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ecl.2016.04.016","volume":"45","author":"DB Sarwer","year":"2016","unstructured":"Sarwer DB, Polonsky HM (2016) The psychosocial burden of obesity. Endocrinol Metab Clin North Am 45:677\u2013688. https:\/\/doi.org\/10.1016\/j.ecl.2016.04.016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1564_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.appet.2013.09.017","volume":"72","author":"N Lasikiewicz","year":"2014","unstructured":"Lasikiewicz N, Myrissa K, Hoyland A, Lawton CL (2014) Psychological benefits of weight loss following behavioural and\/or dietary weight loss interventions. A systematic research review. Appetite 72:123\u2013137. https:\/\/doi.org\/10.1016\/j.appet.2013.09.017","journal-title":"Appetite"},{"key":"1564_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000454837","volume":"9","author":"N-A Weinberger","year":"2016","unstructured":"Weinberger N-A, Kersting A, Riedel-Heller SG, Luck-Sikorski C (2016) Body dissatisfaction in individuals with obesity compared to normal-weight individuals: a systematic review and meta-analysis. Obes Facts 9:424\u2013441. https:\/\/doi.org\/10.1159\/000454837","journal-title":"Obes Facts"},{"key":"1564_CR47","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00420-017-1240-0","volume":"90","author":"LL Andersen","year":"2017","unstructured":"Andersen LL, Izquierdo M, Sundstrup E (2017) Overweight and obesity are progressively associated with lower work ability in the general working population: cross-sectional study among 10,000 adults. Int Arch Occup Environ Health 90:779\u2013787. https:\/\/doi.org\/10.1007\/s00420-017-1240-0","journal-title":"Int Arch Occup Environ Health"},{"key":"1564_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01564-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:59:55Z","timestamp":1762282795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01564-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"25 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"93"}}